Prothena cuts 63% of workforce, expects $16-20M severance costs; two C-suite execs to leave Aug 1

PROTHENA CORP PUBLIC LTD CO

Workforce reduction of ~63% to cut operating costs; substantially complete by Q4 2025.
Expected severance and benefits $16-20M plus non-cash stock option acceleration.
Chief Regulatory Officer Carol D. Karp and Chief People Officer David A. Ford to depart Aug 1, 2025.
Follows May 23 decision to discontinue birtamimab development.

item 2.05item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Carol D. Karp

Chief Regulatory Officer

PRTA · PROTHENA CORP PUBLIC LTD CO

Effective: 2025-08-01
Filed: Jun 18, 2025 23:59 UTC

On June 18, 2025, the Company announced that in connection with the workforce reduction, the employment of Carol D. Karp, the Company’s Chief Regulatory Officer, and David A. Ford, the Company’s Chief People Officer, will terminate effective August 1, 2025.

Departed

David A. Ford

Chief People Officer

PRTA · PROTHENA CORP PUBLIC LTD CO

Effective: 2025-08-01
Filed: Jun 18, 2025 23:59 UTC

On June 18, 2025, the Company announced that in connection with the workforce reduction, the employment of Carol D. Karp, the Company’s Chief Regulatory Officer, and David A. Ford, the Company’s Chief People Officer, will terminate effective August 1, 2025.

Source: SEC EDGAR

accession 0001193125-25-142725

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.